Ossica (Ibandronate Sodium Hydrate)

Ossica is a bisphosphonate that acts on bone metabolism to reduce fracture risk in several skeletal conditions.

• Post‑menopausal osteoporosis: improves the bone mineral density and lowers the risk of vertebral fractures.
• Male osteoporosis: helps the increase the bone mass and decreases fracture incidence.
• Glucocorticoid‑induced osteoporosis: mitigates the bone‑loss caused by long‑term steroid use.
• Paget’s disease of the bone (though only in some regions off label use but recognised in guidelines for bisphosphonates).

• Ibandronate binds to hydroxy‑apatite crystals in bone, where it is taken up by osteoclasts during resorption. The drug inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast function and inducing apoptosis, which reduces bone turnover and increases bone mineral density.

Adverse reactions to ibandronate are reported across a spectrum of frequency.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia.
• Musculoskeletal pain: transient bone, joint or muscle aches.
• Flu‑like symptoms: mild fever, chills, fatigue.
• Headache.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ).
• Atypical femoral fractures.
• Severe esophagitis or esophageal ulceration.
• Acute renal impairment.
• Hypocalcaemia.
• Severe allergic reactions (anaphylaxis).

When prescribing ibandronate, clinicians should assess patient history and monitor for specific risks.

• Renal function: evaluate baseline creatinine and adjust use if impairment present.
• Calcium/Vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
• Gastro‑intestinal health: advise patients to remain upright for at least 30 minutes after dosing.
• Concomitant medications: review for drugs that may affect absorption or renal function.
• Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Ibandronate may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid)

• Antacids or supplements containing calcium, magnesium, aluminium, or iron: reduce ibandronate absorption.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) combined with high‑dose ibandronate: increase risk of gastrointestinal ulceration.\nModerate ...